Notable Yale Exits
These Yale spinouts represent successful acquisitions and IPOs since 2018 — each built on rigorous Yale science, backed by Yale Ventures, and brought to the patients, industries, and markets that needed them most.
Quantum Circuits, Inc.
Halda Therapeutics
Inozyme Pharma
Quantum Circuits developed a "correct first, then scale" approach to commercializing quantum computing, using built-in error detection to produce stable systems with consistent results.
Halda Therapeutics developed RIPTAC therapeutics — a hold-and-kill mechanism designed to precisely target cancer cells and overcome resistance that evolves during treatment.
Inozyme Pharma developed therapeutics targeting the PPi-Adenosine Pathway, an essential regulator of bone health and vascular function whose disruption underlies several severe diseases.
Co-founders: Robert Schoelkopf, PhD, Michel Devoret, PhD and Luigi Frunzio, PhD
Founder: Craig Crews, PhD
Founder: Demetrios Braddock, MD, PhD
Acquired by D-Wave
JANUARY 2026
Acquired by Johnson & Johnson
DECEMBER 2025
Acquired by BioMarin
JULY 2025
ModifiBio
Isoplexis
Biohaven
ModifiBio developed molecules that kill cancer cells through direct DNA modification — a mechanism cancer cells with DNA repair defects cannot reverse.
Isoplexis developed single-cell proteomics technology, including the IsoSpark platform, that revealed how multifunctional immune cells communicate — giving researchers deeper insight into cell behavior and function.
Biohaven built a pipeline of treatments across immunology, obesity, neuroscience, and oncology, focused on diseases with limited or no existing therapeutic options.
Co-Founders: Ranjit Bindra, MD; Seth Herzon, PhD; Kingson Lin ’24, PhD, MD
Co-founders: Rong Fan PhD, Sean Mackay MBA ’14
Founder: Vlad Coric, MD
Acquired by Merck
OCTOBER 2024
Acquired by Merck
OCTOBER 2024
Acquired by Pfizer
OCTOBER 2022
Alexion
NextCure
Arvinas
Alexion developed treatments and therapies for rare disease patients globally, with a focus on improving outcomes for conditions that have historically lacked therapeutic options.
NextCure developed biopharmaceutical therapies targeting cancer types underserved by existing treatments — with particular focus on patients whose cancer resists or progresses through current therapies.
Arvinas developed targeted protein degradation therapies for cancer and other serious diseases, using its PROTAC platform to eliminate disease-causing proteins rather than merely inhibit them.
Founder: Leonard Bell, PhD
IPO
FERBRUARY 1996
Acquired by AstraZeneca
JULY 2021
Founder: Lieping Chen MD, PhD
IPO
MAY 2019
Founder: Craig Crews, PhD
IPO
SEPTEMBER 2018